Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Interdisciplinary Communication
Male
Middle Aged
Neoplasm Recurrence, Local
/ mortality
Neoplasms
/ mortality
Patient Care Team
/ organization & administration
Prognosis
Retrospective Studies
Survival Rate
Young Adult
Cancer
Matched pair analysis
Multidisciplinary tumor board
Overall survival
Relapse free survival
Time to progression
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Apr 2020
28 Apr 2020
Historique:
received:
02
08
2019
accepted:
31
03
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
3
2
2021
Statut:
epublish
Résumé
This analysis aims at evaluating the impact of multidisciplinary tumor boards on clinical outcome of multiple tumor entities, the effect of the specific number of multidisciplinary tumor boards and potential differences between the tumor entities. By a matched-pair analysis we compared the response to treatment, overall survival, relapse or disease free survival and progression free survival of patients whose cases were discussed in a tumor board meeting with patients whose cases were not. It was performed with patients registered in the cancer registry of the University of Bonn and diagnosed between 2010 and 2016. After the matching process with a pool of 7262 patients a total of 454 patients with 66 different tumor types were included in this study. First, patients with three or more multidisciplinary tumor board meetings in their history show a significantly better overall survival than patients with no tumor board meeting. Second, response to treatment, relapse free survival and time to progression were not found to be significantly different. Third, there was no significant difference for a specific tumor entity. This study revealed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome. Also, our analysis hints towards a positive effect of multidisciplinary tumor boards on overall survival.
Sections du résumé
BACKGROUND
BACKGROUND
This analysis aims at evaluating the impact of multidisciplinary tumor boards on clinical outcome of multiple tumor entities, the effect of the specific number of multidisciplinary tumor boards and potential differences between the tumor entities.
METHODS
METHODS
By a matched-pair analysis we compared the response to treatment, overall survival, relapse or disease free survival and progression free survival of patients whose cases were discussed in a tumor board meeting with patients whose cases were not. It was performed with patients registered in the cancer registry of the University of Bonn and diagnosed between 2010 and 2016. After the matching process with a pool of 7262 patients a total of 454 patients with 66 different tumor types were included in this study.
RESULTS
RESULTS
First, patients with three or more multidisciplinary tumor board meetings in their history show a significantly better overall survival than patients with no tumor board meeting. Second, response to treatment, relapse free survival and time to progression were not found to be significantly different. Third, there was no significant difference for a specific tumor entity.
CONCLUSION
CONCLUSIONS
This study revealed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome. Also, our analysis hints towards a positive effect of multidisciplinary tumor boards on overall survival.
Identifiants
pubmed: 32345242
doi: 10.1186/s12885-020-06809-1
pii: 10.1186/s12885-020-06809-1
pmc: PMC7189747
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355Subventions
Organisme : Deutsche Krebshilfe
ID : 70113470
Références
J Natl Cancer Inst. 2013 Jan 16;105(2):113-21
pubmed: 23274388
Ann Oncol. 2018 Feb 1;29(2):341-346
pubmed: 29140422
PLoS One. 2019 Jan 14;14(1):e0210730
pubmed: 30640924
Lung Cancer. 2018 Oct;124:199-204
pubmed: 30268461
BMC Cancer. 2018 Sep 29;18(1):936
pubmed: 30268109
BMJ. 2012 Apr 26;344:e2718
pubmed: 22539013
Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1199-1204
pubmed: 29293943
Dtsch Med Wochenschr. 2017 May;142(9):e51-e60
pubmed: 28241373
Clin Lung Cancer. 2018 Jul;19(4):346-351
pubmed: 29506890
Ann Surg Oncol. 2014 Apr;21(4):1287-95
pubmed: 24318095
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552
Head Neck. 2016 Apr;38 Suppl 1:E1544-53
pubmed: 26890807
Laryngoscope. 2020 Apr;130(4):946-950
pubmed: 31095740
Colorectal Dis. 2011 Dec;13(12):1361-9
pubmed: 20958913
HPB (Oxford). 2017 Feb;19(2):133-139
pubmed: 27916436